By Colin Kellaher

 

Bayer AG (BAYN.XE) on Monday said the U.S. Food and Drug Administration approved the company's Gadavist injection for use in cardiac magnetic resonance imaging in adults with known or suspected coronary artery disease.

The Leverkusen, Germany, chemical-and-pharmaceutical company said Gadavist is the first and only FDA-approved contrast agent for such use.

Cardiac magnetic resonance imaging is an important diagnostic tool in the battle against coronary artery disease, which affects about 16.5 million Americans, Bayer said.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

July 15, 2019 10:27 ET (14:27 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.